The provider discusses how the injection is given (in the abdomen, thigh, or upper arm) and reviews possible side effects
The STEP trials demonstrated weight reductions of approximately 14.9% on average, and the SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events in overweight and obese non-diabetic patients, transforming obesity into a cardiovascular indication and massively expanding the prescribing universe and reimbursement coverage
Last Update: May 12, 2023
Avoid self-prescribing, as it can lead to poor results or unnecessary risks.
Lower doses still produced meaningful results, but the greatest reductions were seen at the upper end of the dosing range
tirzepatide: 5, 10, and 15 mg)